Navigation

Personal tools

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit https://cc.nih.gov/.

Updates regarding government operating status and resumption of normal operations can be found at https://USA.gov/.

You are here: Home / Protocols / Proteomics Biomarker Development Laboratory

Proteomics Biomarker Development Laboratory

53

No lead investigator defined.

No coordinating investigator defined.

No involved investigator sites defined.

UNKNOWN

The Biomarker Development Laboratory is focused on the application of a proteomic approach for the development of cancer biomarkers. The laboratory will apply technologies for protein analysis to the detection and identification of proteins secreted by tumor cells and protein antigens that induce a humoral response in tumors. The initial targeted tumor types for the identification of potential biomarker proteins are: Colon, esophagus, ovary, lung, breast and liver. The proposed studies will make heavy utilization of two-dimensional (2-D) protein analysis, of protein identification technologies and of database capabilities that have been developed by the applicant group. The objectives of this research are to 1. Identify tumor antigens that induce a humoral response; 2. Identify tumor secreted proteins and developa database; 3. Preliminarily validate the potential utilityof markers for early cancer detection. Sixty ml of bloodwill be obtained from healthy normals, and from small cell lung cancer, hepatoma, esophageal, and breast cancerpatients, and from ovarian, colon, and non-small cell lungcancer patients prior to surgical resection and six toten weeks after resection. Demographic data, sera and DNA will be used in 2-D protein analysis to identify newor altered proteins. The initial validation will be the assay of the presence or absence of a given protein in alarge sample cohort from the samples collected from thesepatients. There is no specified age range, although the diseases under study do not occur in children. No subjectswill be excluded on the basis of race or gender. Womenof child bearing age will be studied. Linkable demographicdata will be held separately from the bar-coded serum orDNA samples. Serum and DNA sample will be identifiableonly by subject identification number. Full written informed consent will be obtained from patients.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Announcement 10/23/2017

Three new FOAs on the Human Tumor Atlas and associated with the Cancer Moonshot Initiative have been released. Please click here for more information.

10th Science Workshop
Thank you to everyone who made the 32nd EDRN Steering Committee meeting a success. The next event is the 10th EDRN Scientific Workshop from March 6-8, 2018 in Bethesda, MD. Click to view the flyer; click to visit the registration page.
EDRN Founder Honored

Dr. Sudhir Srivastava was honored with the Distinguished Service Award from the American Pancreatic Association at the group's annual meeting this year, for his outstanding commitment to pancreatology.